Program
Ribavirin
Also written as “ribavirin”, “RBV” and “Ribavirin (RBV)”.
Its studies are mostly in Hepatitis C, Chronic · Hepatitis C · Hepatic Insufficiency · Hepatitis, Chronic · Anemia, led by 19 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 320 open or running | phase 4since Feb 10, 2004 | Feb 10, 2004 | none ahead |
| Merck | 310 open or running | phase 4since Sep 12, 2005 | Jun 13, 2002 | none ahead |
| AbbVie | 240 open or running | phase 3since Sep 28, 2012 | Feb 28, 2011 | none ahead |
| Gilead Sciences | 190 open or running | phase 4since Apr 29, 2014 | Dec 13, 2010 | none ahead |
| Vertex Pharmaceuticals | 110 open or running | phase 4since Nov 3, 2011 | Jul 27, 2004 | none ahead |
| Bristol-Myers Squibb | 80 open or running | phase 3since Dec 12, 2014 | Mar 4, 2011 | none ahead |
| Johnson & Johnson | 50 open or running | phase 3since Jun 19, 2008 | Jun 19, 2008 | none ahead |
| Tanabe Pharma | 40 open or running | phase 3since Nov 2, 2011 | Feb 24, 2008 | none ahead |
| ortho-biotech-products-l-p | 20 open or running | phase 2since Apr 14, 2006 | Apr 14, 2006 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| biolex-therapeutics-inc | 10 open or running | phase 2since Aug 5, 2009 | Aug 5, 2009 | none ahead |
| biolinerx-ltd | 10 open or running | phase 2since Apr 15, 2013 | Apr 15, 2013 | none ahead |
| fgk-clinical-research-gmbh | 10 open or running | phase 4since Jul 11, 2006 | Jul 11, 2006 | none ahead |
| getz-pharma | 10 open or running | phase 4since Nov 2, 2015 | Nov 2, 2015 | none ahead |
| icn-pharmaceuticals | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| janssen-infectious-diseases-bvba | 10 open or running | phase 3since Oct 28, 2010 | Oct 28, 2010 | none ahead |
| kawin-technology-share-holding-co-ltd | 10 open or running | no phasesince Feb 27, 2018 | Feb 27, 2018 | none ahead |
| nanogen-pharmaceutical-biotechnology-joint-stock-company | 10 open or running | phase 4since Apr 3, 2025 | Apr 3, 2025 | none ahead |
| Novartis | 10 open or running | phase 1since Aug 13, 2009 | Aug 13, 2009 | none ahead |
Also a collaborator on its studies: toray-industries-inc, dimension-research, ppd-development-lp, integrated-therapeutics-group, roche-pharma-ag, virochem-pharma, tibotec-pharmaceutical-limited and viropharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Sep 27, 2012.
- Nov 18, 2015Phase 3 study in Hepatitis CAbbVie · NCT02609659 · 105 enrolled
- Dec 11, 2015Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02641379 · 737 enrolled · Austria
- Jan 28, 2016Phase 3 study in Hepatitis CBristol-Myers Squibb · NCT02673489 · 106 enrolled · United States, Canada
- Mar 18, 2016Phase 2 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02716779 · 68 enrolled · Germany
- Apr 11, 2016Phase 3 study in Hepatitis CGilead Sciences · NCT02738333 · 239 enrolled · Japan
- May 3, 2016Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02761629 · 180 enrolled · Brazil
- May 20, 2016Phase 2 study in Hepatitis CGilead Sciences · NCT02781558 · 204 enrolled · Spain
- May 31, 2016Phase 3 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02791256 · 23 enrolled · Belgium
- Jun 30, 2016Phase 3 study in Hepatitis CGilead Sciences · NCT02822794 · 117 enrolled · Japan
- Aug 9, 2016Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02864199 · 63 enrolled · United States, Brazil, France and more
- Dec 13, 2016Phase 2 study in Hepatitis CGilead Sciences · NCT02994056 · 32 enrolled · United States, France
- Dec 15, 2016Phase 3 study in Hepatitis CGilead Sciences · NCT02996682 · 102 enrolled · Japan
- Feb 27, 2018kawin-technology-share-holding-co-ltd's first study: no phase study in Hepatitis C, ChronicNew to kawin-technology-share-holding-co-ltdkawin-technology-share-holding-co-ltd · NCT03453346 · 136 enrolled · China
- Apr 3, 2025nanogen-pharmaceutical-biotechnology-joint-stock-company's first study: phase 4 study in Hepatitis C, ChronicNew to nanogen-pharmaceutical-biotechnology-joint-stock-companynanogen-pharmaceutical-biotechnology-joint-stock-company · NCT06922643 · 100 enrolled
TargetBeta
“Inosine-5'-monophosphate dehydrogenase 1 inhibitor; RNA-directed RNA polymerase inhibitor; RNA inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 147 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06922643Hepatitis C, Chronic | 4 | Completed | nanogen-pharmaceutical-biotechnology-joint-stock-company | Jan 21, 2013 | 100 |
| NCT03453346Hepatitis C, Chronic · China | – | Completed | kawin-technology-share-holding-co-ltd | Mar 18, 2017 | 136 |
| NCT02996682Hepatitis C · Japan | 3 | Completed | Gilead Sciences | Feb 13, 2018 | 102 |
| NCT02994056Hepatitis C · United States, France | 2 | Completed | Gilead Sciences | Sep 25, 2018 | 32 |
| NCT02864199Hepatitis C, Chronic · United States, Brazil, France and more | 4 | Completed | Hoffmann-La Roche | Sep 2007 | 63 |
| NCT02822794Hepatitis C · Japan | 3 | Completed | Gilead Sciences | Jun 2, 2017 | 117 |
| NCT02791256Hepatitis C, Chronic · Belgium | 3 | Terminated | Hoffmann-La Roche | Jun 2008 | 23 |
| NCT02781558Hepatitis C · Spain | 2 | Completed | Gilead Sciences | Oct 6, 2017 | 204 |
| NCT02761629Hepatitis C, Chronic · Brazil | 4 | Completed | Hoffmann-La Roche | May 2008 | 180 |
| NCT02738333Hepatitis C · Japan | 3 | Completed | Gilead Sciences | Feb 14, 2017 | 239 |
| NCT02716779Hepatitis C, Chronic · Germany | 2 | Completed | Hoffmann-La Roche | Apr 2010 | 68 |
| NCT02673489Hepatitis C · United States, Canada | 3 | Completed | Bristol-Myers Squibb | Mar 2, 2017 | 106 |
| NCT02641379Hepatitis C, Chronic · Austria | 4 | Completed | Hoffmann-La Roche | Nov 2013 | 737 |
| NCT02609659Hepatitis C | 3 | Completed | AbbVie | Oct 7, 2016 | 105 |
| NCT02600351Hepatitis C · United States, Canada, Puerto Rico | 3 | Terminated | Gilead Sciences | Mar 21, 2017 | 87 |
| NCT02601976Hepatitis C | 4 | Completed | getz-pharma | Sep 2012 | 64 |
| NCT02551861Hepatitis C · Canada, France | 2 | Withdrawn | Bristol-Myers Squibb | Jun 2016 | 0 |
| NCT02493855Hepatitis C, Chronic | 2 | Completed | AbbVie | Apr 2016 | 46 |
| NCT02487030Hepatitis C · Egypt | 3 | Completed | Gilead Sciences | Nov 11, 2016 | 255 |
| NCT02486406Hepatitis C · United States, Belgium, Germany and more | 3 | Completed | AbbVie | Nov 19, 2020 | 64 |
| NCT02472886Hepatitis C · Estonia, Russian Federation | 3 | Completed | Gilead Sciences | Mar 30, 2016 | 153 |
| NCT02446717Hepatitis C, Chronic | 3 | Completed | AbbVie | Dec 2016 | 141 |
| NCT02442284Hepatitis C, Chronic | 3 | Completed | AbbVie | Aug 22, 2016 | 99 |
| NCT02442271Hepatitis C, Chronic | 3 | Completed | AbbVie | Jul 4, 2016 | 222 |
| NCT02399345Hepatitis C, Chronic | 3 | Completed | AbbVie | Nov 2015 | 10 |
| NCT02358044Hepatitis C | 3 | Completed | Merck | Nov 26, 2015 | 257 |
| NCT02356562Hepatitis C | 2 | Completed | AbbVie | Oct 28, 2016 | 29 |
| NCT02319031Hepatitis C · Australia, France | 3 | Completed | Bristol-Myers Squibb | Oct 2015 | 53 |
| NCT02249182Hepatitis C · United States, Australia, New Zealand and more | 2 | Completed | Gilead Sciences | Jun 15, 2018 | 226 |
| NCT02247401Hepatitis C | 3 | Completed | AbbVie | Aug 1, 2016 | 160 |
| NCT02243293Hepatitis C, Chronic | 3 | Completed | AbbVie | Oct 25, 2016 | 694 |
| NCT02220998Hepatitis C · United States, Puerto Rico | 3 | Completed | Gilead Sciences | Jul 2015 | 269 |
| NCT02219477Hepatitis C, Chronic | 3 | Completed | AbbVie | Jun 13, 2016 | 36 |
| NCT02201953Hepatitis C · United States, Australia, Canada and more | 3 | Completed | Gilead Sciences | Sep 2015 | 558 |
| NCT02175966Hepatitis C · United States | 2 | Completed | Bristol-Myers Squibb | Jan 28, 2015 | 35 |
| NCT02175758Hepatitis C · United States, Australia, Belgium and more | 2 | Completed | Gilead Sciences | Jun 21, 2018 | 106 |
| NCT02128542Hepatitis C · United States | 4 | Completed | Gilead Sciences | Jun 2015 | 66 |
| NCT02120300Chronic HCV Infection · United States | 2 | Completed | Gilead Sciences | Aug 2015 | 122 |
| NCT02068222Hepatitis C, Chronic | 2 | Completed | AbbVie | Mar 2015 | 10 |
| NCT02023112Hepatitis C | 3 | Completed | AbbVie | Apr 2015 | 171 |
| NCT01962441Hepatitis C · United States, Australia, Canada and more | 3 | Completed | Gilead Sciences | Jan 7, 2015 | 601 |
| NCT01945294Hepatitis C, Chronic | 3 | Completed | Merck | Aug 5, 2015 | 257 |
| NCT01939197Hepatitis C | 3 | Completed | AbbVie | Jul 21, 2016 | 318 |
| NCT01938625Hepatitis C, Chronic · Germany, Poland, Spain | 2 | Completed | Johnson & Johnson | Apr 27, 2015 | 35 |
| NCT01853254Hepatitis C, Chronic · United States, Australia, Brazil and more | 3 | Completed | Hoffmann-La Roche | Sep 2011 | 272 |
| NCT01852604Hepatitis C, Chronic | 2 | Completed | Merck | Apr 2015 | 143 |
| NCT01833845Hepatitis C · France | 2 | Terminated | biolinerx-ltd | Apr 2014 | 4 |
| NCT01854697Hepatitis C, Chronic | 3 | Completed | AbbVie | Nov 2014 | 311 |
| NCT01826981Hepatitis C, Chronic · New Zealand | 2 | Completed | Gilead Sciences | Mar 2015 | 359 |
| NCT01833533Hepatitis C, Chronic | 3 | Completed | AbbVie | Dec 2013 | 305 |
| NCT01795911Hepatitis C · United States | 2 | Completed | Bristol-Myers Squibb | Apr 2014 | 165 |
| NCT01782495Hepatitis, Chronic | 2 | Completed | AbbVie | Nov 2, 2016 | 129 |
| NCT01770223Hepatitis C | 4 | Withdrawn | Merck | Dec 2015 | 0 |
| NCT01753570Hepatitis C, Chronic · Japan | 3 | Completed | Tanabe Pharma | Oct 2015 | 74 |
| NCT01767116Hepatitis C, Chronic | 3 | Completed | AbbVie | Dec 2013 | 419 |
| NCT01715415Hepatitis C | 3 | Completed | AbbVie | Nov 2013 | 395 |
| NCT01716585Hepatitis C | 3 | Completed | AbbVie | Oct 2013 | 636 |
| NCT01704755Fibrosis | 3 | Completed | AbbVie | Jan 2014 | 381 |
| NCT01697436Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Dec 2012 | 40 |
| NCT01701063Hepatitis C · United States, Belgium, Germany and more | 2 | Terminated | Vertex Pharmaceuticals | Apr 2015 | 42 |
How it is read
Names in the registry
- “Ribavirin”, 93 entries
- “ribavirin”, 26 entries
- “RBV”, 21 entries
- “Ribavirin (RBV)”, 11 entries
- “ribavirin [Copegus]”, 7 entries
Conditions, from the studies’ own filings
- Hepatitis C, Chronic, 107 studies
- Hepatitis C, 54 studies
- Hepatic Insufficiency, 1 study
- Hepatitis, Chronic, 1 study
- Anemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.